Literature DB >> 30087729

Assessment of the Role of the Anti-Mullerian Hormone, Luteinizing Hormone/Follicle Stimulating Hormone Ratio in the Diagnosis of Polycystic Ovary Syndrome in Sudanese Women.

Hafza Tola1, Mohammed Abbas2, Elsir Abu Alhassan3, Nassr Eldin Shrif1, Mohammed Rida3.   

Abstract

BACKGROUND: The diagnosis of polycystic ovary syndrome (PCOS) is not an easy procedure, as the signs and symptoms are heterogeneous and of undefined aetiology. AIM: This study is aimed to evaluate serum anti-Mullerian hormone (AMH) level and luteinizing hormone (LH)/folic stimulating hormone (FSH) ratio in women with PCOS in Sudan and to assess the diagnostic efficiency for the diagnosis of PCOS.
METHODS: In a case-control study, Serum AMH, LH, FSH was measured in the early follicular phase from Sudanese patients (N = 230) with PCOS and100 controls. The LH/FSH ratio was calculated, and its diagnostic power was evaluated by receiver operating characteristic curves.
RESULTS: The means of serum AMH, serum LH level and LH/FSH ratio of the test, were significantly increased in the test group compared to the control group (P-value < 0.000). The AMH sensitivity, specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) were found to be 83%, 99%, 99%, and 72% respectively. Serum AMH was considered adequate measures for the diagnosis of PCOS; its level showed an area under the ROC curve of 0.98 (95% confidence, P-value < 0.000). The best compromise between 98% specificity and 90% sensitivity was obtained with a cut-off value of 3.3 ng/mL for PCOS diagnosis. There was no correlation between age, body mass index (BMI) and AMH level in the test group.
CONCLUSIONS: The Serum AMH level and LH/FSH ratio were higher in patients than in control. However AMH level has better discriminative power and good diagnostic potency for the diagnosis of the PCOS among Sudanese women.

Entities:  

Keywords:  Anti-Müllerian hormone; Follicle Stimulating Hormone; Luteinizing Hormone; Ovulation; Polycystic Ovary Syndrome; Sudanese women

Year:  2018        PMID: 30087729      PMCID: PMC6062285          DOI: 10.3889/oamjms.2018.260

Source DB:  PubMed          Journal:  Open Access Maced J Med Sci        ISSN: 1857-9655


  14 in total

1.  Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome.

Authors:  P Pigny; S Jonard; Y Robert; D Dewailly
Journal:  J Clin Endocrinol Metab       Date:  2005-12-20       Impact factor: 5.958

Review 2.  Role of lifestyle modification in the management of polycystic ovary syndrome.

Authors:  Kathleen M Hoeger
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2006-06       Impact factor: 4.690

3.  Anti-Mullerian hormone confirms the novel classification of female functional androgenization including polycystic ovary syndrome.

Authors:  B Wetzka; W Textor; A Ochsner; F Geisthövel
Journal:  Eur J Endocrinol       Date:  2011-05-20       Impact factor: 6.664

Review 4.  Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.

Authors:  Mark O Goodarzi; Daniel A Dumesic; Gregorio Chazenbalk; Ricardo Azziz
Journal:  Nat Rev Endocrinol       Date:  2011-01-25       Impact factor: 43.330

5.  Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome.

Authors:  Lin Li; Xiaoli Chen; Yaqin Mo; Yaxiao Chen; Meiying Wenig; Dongzi Yang
Journal:  Wien Klin Wochenschr       Date:  2010-09-03       Impact factor: 1.704

6.  Differences of the association of anti-Müllerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome.

Authors:  Hee-Yeon Woo; Kye-Hyun Kim; Eun-Jung Rhee; Hyosoon Park; Mi-Kyung Lee
Journal:  Endocr J       Date:  2012-05-19       Impact factor: 2.349

7.  Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features.

Authors:  Melissa Pawelczak; Lisa Kenigsberg; Sarah Milla; Ying-Hua Liu; Bina Shah
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

8.  Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome.

Authors:  Sezai Sahmay; Nil Atakul; Begüm Aydogan; Yavuz Aydin; Metehan Imamoglu; Hakan Seyisoglu
Journal:  Acta Obstet Gynecol Scand       Date:  2013-10-15       Impact factor: 3.636

9.  Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS).

Authors:  Roger Hart; Dorota A Doherty; Robert J Norman; Stephen Franks; Jan E Dickinson; Martha Hickey; Deborah M Sloboda
Journal:  Fertil Steril       Date:  2010-01-08       Impact factor: 7.329

10.  The circadian variation in Anti-Müllerian hormone in patients with polycystic ovary syndrome differs significantly from normally ovulating women.

Authors:  Leif Bungum; Florencia Franssohn; Mona Bungum; Peter Humaidan; Aleksander Giwercman
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

View more
  2 in total

1.  Analysis of Endocrine and Metabolic Indexes in Non-Obese Patients with Polycystic Ovary Syndrome and Its Compare with Obese Patients.

Authors:  Wenjing Shi; Qi Zhao; Xue Zhao; Chuan Xing; Bing He
Journal:  Diabetes Metab Syndr Obes       Date:  2021-10-15       Impact factor: 3.168

2.  Age-specific cut-off levels of anti-Müllerian hormone can be used as diagnostic markers for polycystic ovary syndrome.

Authors:  Fahimeh Ramezani Tehrani; Maryam Rahmati; Fatemeh Mahboobifard; Faezeh Firouzi; Nazanin Hashemi; Fereidoun Azizi
Journal:  Reprod Biol Endocrinol       Date:  2021-05-22       Impact factor: 5.211

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.